Clinical trials: GVHD,Acute
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
SRL (Sirolimus) Withdrawal
The significance of this clinical trial lies in its potential to increase the success of immunosuppression (IS) therapy withdrawal in liver transplant (LT) recipients, thus decreasing the negative impact of IS on their long-term…
- Trial name
- SRL (NCT02062944)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Ulcerative Colitis
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who are in remission.
- Trial name
- PACE (NCT02093663)
- Testing
- MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Shire
Acute Myelogenous Leukemia (AML)
Omacetaxine for Consolidation and Maintenance
The purpose of this pilot study is to assess the safety and tolerability of omacetaxine for consolidation in patients age 55 and older with acute myelogenous leukemia (AML) in first complete remission following induction with…
- Trial name
- NCT01873495
- Testing
- Omacetaxine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Emory University
Acute Appendicitis
Appendicectomy Versus Antibiotics in the Treatment of Acute Uncomplicated Appendicitis
Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a "routine" operation.
- Trial name
- APPAC (NCT01022567)
- Testing
- Appendicectomy, Ertapenem
- Where
- 6 sites in Finland
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
This pilot study has been designed to investigate the safety of pembrolizumab treatment for disease relapse following allogeneic stem cell transplant (alloSCT).
- Conditions
- Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02981914
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
RSV Infection
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications…
- Trial name
- RSVHR (NCT05568706)
- Testing
- EDP-938
- Where
- 84 sites in United States, Argentina and 10 more
- Volunteers
- 187 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Patient Experience, Medical Emergencies
Effectiveness and Clinical Outcomes of Municipal Acute Wards Versus a General Hospital
Demographic changes in the industrialized world are expected to prompt a need for better organized and more efficient health care services.
- Conditions
- Patient Experience, Medical Emergencies, Mortality, Morbidity
- Trial name
- NCT03885206
- Testing
- Level of healthcare services
- Where
- Norway
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Ostfold University College
Acute Lymphoblastic Leukemia
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
- Trial name
- NCT01685021
- Testing
- MOR00208 (formerly Xmab5574)
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- MorphoSys AG
Otitis Media, Infections, Respiratory Tract
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
Augmentin (ES)-600 is a high-dose amoxicillin/clavulanic acid 14:1 formulation that allows administration at 90/6.4 milligrams (mg)/kilograms (kg)/day in two divided doses.
- Conditions
- Otitis Media, Infections, Respiratory Tract, Respiratory Tract Infections
- Trial name
- NCT04600752
- Testing
- Augmentin (ES)-600
- Where
- 13 sites in India
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Post-acute Covid-19 Syndrome
Homeopathic Treatment of Post-acute COVID-19 Syndrome
To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of…
- Trial name
- NCT05104749
- Testing
- Homeopathic Medication
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Southwest College of Naturopathic Medicine
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
HIV Infections
Anti-HIV Medications for People Recently Infected With HIV
It is not known if anti-HIV treatment for recently infected patients improves long-term patient prognosis. The purpose of this study is to determine if a one year course of anti-HIV medications slows progression of HIV disease in…
- Trial name
- NCT00106171
- Testing
- Highly active antiretroviral therapy (HAART)
- Where
- 5 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
SARS-CoV-2 Infection, Acute Kidney Injury
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+)…
- Trial name
- NIRVANA (NCT04818216)
- Testing
- Nicotinamide riboside
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Post-Operative Pain
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
The study is intended to show that the Sufentanil NanoTab PCA System is as effective as morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery.
- Trial name
- NCT01539538
- Testing
- Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA
- Where
- 16 sites in United States
- Volunteers
- 357 people
- Sponsor
- Talphera, Inc
Chronic Rhinosinusitis, Recurrent Acute Rhinosinusitis
Global Sinus Surgery Registry
This study evaluates long-term safety and effectiveness of primary sinus surgery in a real-world population of adults with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS).
- Trial name
- OASIS (NCT02347943)
- Where
- 25 sites in United States
- Volunteers
- 252 people
- Sponsor
- Integra LifeSciences Corporation
Sickle Cell Disease
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises.
- Trial name
- NCT00834899
- Testing
- Eptifibatide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Acute, Post-operative Pain
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427
This randomized, double-blind, placebo controlled, study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of ST-2427.
- Trial name
- NCT04475198
- Testing
- ST-2427
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- SiteOne Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.